Don't miss it! On Wednesday, 26 Nov 2026, 6 pm CET, EASL Studio hosts a new episode titled “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance.” This session will explore the clinical value of rifaximin in the management of hepatic encephalopathy while addressing the growing concerns surrounding antimicrobial resistance - featuring both MICROB-PREDICT's coordinator Jonel Trebicka, as well as A-TANGO's coordinator Rajiv Jalan, together with colleagues Vishal Patel as co-speaker and Debbie Shawcross as moderator.  The EASL Studio episode will be broadcast live and can be accessed here. It will also be available to watch on demand on EASL Campus from Thursday, 27 November.

We are celebrating the completion of the first site visit for A-TANGO's clinical trial: Thanks to huge efforts by Yaqrit and the whole team, we have officially kicked off our Phase 2a trial, evaluating the safety of a novel intravenous TLR-4 antagonist in combination with granulocyte-colony stimulating factor (G-CSF) for the treatment of acute-on-chronic liver failure (ACLF) grades 1 and 2. We call this new combinatorial therapy "G-TAK". This novel therapy offers new hope for liver failure patients and aims to restore some liver functionality and improve patient outcomes. A huge thank you goes out to the Royal Free Hospital, UK, for their warm welcome and dedication to patient-first research. Special recognition goes to the clinical study supervisor Prof. Cornelius Engelmann from the Charité and to Clinical Operations Lead Carrie Morgan from Yaqrit.

What an inspiring and productive  9th Steering Committee (SC) Meeting! It was lovely to meet the liver-health enthusiasts and clinical investigators who recently joined our G-TAK Study! The first half of the SC Meeting addressed many questions our valued colleagues from the United Kingdom (UK) and India had. The second half of today's agenda consisted of progress reports from work packages WP1, WP2, WP3, WP7, and WP8, leading to important discussions and decisions. Let's roll up our sleeves now to sign further study site contracts in the UK and India to include as many ACLF patients in this study as possible. Bringing an effective treatment for this dangerous disease to the market is an urgent unmet need because the prevalence of decompensated cirrhosis amounts to approximately 10 million cases per year.